1	Using quantitative magnetic resonance
2	imaging to track cerebral alterations in
3	multiple sclerosis brain: a longitudinal
4	study
5 6 7 8 9	Nora Vandeleene ^a , Camille Guillemin ^{a,b} , Solène Dauby ^{a,c} , Florence Requier ^{a,b} , Maëlle Charonitis ^{a,b} , Daphne Chylinski ^{a,b} , Evelyne Balteau ^a , Pierre Maquet ^{a,c} , Emilie Lommers ^{a,c*} , Christophe Phillips ^{a,d*} ^a GIGA CRC in vivo Imaging, University of Liège, Liège, Belgium ^b Psychology and Cognitive Neuroscience Research Unit, University of Liège, Liège,
11 12 13	Belgium ^c Clinical Neuroimmunology Unit, Neurology Department, CHU Liège, Belgium ^d GIGA in silico Medicine, University of Liège, Liège, Belgium
14	* These authors equally contributed to the work.
15 16 17 18 19 20 21	Corresponding author: Christophe PHILLIPS GIGA – CRC in vivo imaging B30 Allée du 6 août 4000 Liège Belgium
22 23 24 25 26	Acknowledgements The authors are particularly thankful for the patients who took part in this study. N.V., E.L. and C.P. are supported by the Fonds de la Recherche Scientifique (F.R.S-FNRS Belgium).
27 28 29 30 31	Data availability The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
32 33 34 35	Conflict interests None.
36	Abbreviations:
37 38	ARoC : Annual Rate of Change, BPF : Brain Parenchymal Fraction, CDP : Confirmed Disability Progression, cMRI : Conventional Magnetic Resonance Imaging, CNS : Central
20	Disability Flogression, civin. Conventional Magnetic Resonance imagnity, CN3: Central

Nervous System, GMF: Grey Matter Fraction, GLMM: General Linear Mixed Model, LF: Lesion Fraction, MPM: Multi-Parameter Mapping, MRI: Magnetic Resonance Imaging, MS: Multiple Sclerosis, MT: Magnetization Transfer, MTR: Magnetization Transfer Ratio, MTsat: Saturated Magnetization Transfer, NABT: Normal Appearing Brain Tissue, NACGM: Normal Appearing Cortical Grey Matter, NADGM: Normal Appearing Deep Grey matter, NAWM: Normal Appearing White Matter, NEDA-3: No Evidence of Disease Activity, RRMS: Relapsing-Remitting Multiple Sclerosis, PD: Proton Density, PMS: Progressive Multiple Sclerosis, qMRI: Quantitative Magnetic Resonance Imaging, R1: Longitudinal Relaxation Rate (1/T1), R2*: Transverse Relaxation Rate (1/T2*), TIV: Total Intracranial Volume, TPM: Tissue Probability Map, US: Unified Segmentation, USwL: Unified Segmentation with Lesion

Abstract

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Quantitative MRI quantifies tissue microstructural properties and supports the characterization of cerebral tissue damages. With an MPM protocol, 4 parameter maps are constructed: MTsat, PD, R1 and R2*, reflecting tissue physical properties associated with iron and myelin contents. Thus, qMRI is a good candidate for in vivo monitoring of cerebral damage and repair mechanisms related to MS. Here, we used qMRI to investigate the longitudinal microstructural changes in MS brain. Seventeen MS patients (age 25-65, 11 RRMS) were scanned on a 3T MRI, in two sessions separated with a median of 30 months, and the parameters evolution was evaluated within several tissue classes: NAWM, NACGM and NADGM, as well as focal WM lesions. An individual annual rate of change for each qMRI parameter was computed, and its correlation to clinical status was evaluated. For WM plagues, three areas were defined, and a GLMM tested the effect of area, time points, and their interaction on each median qMRI parameter value. Patients with a better clinical evolution, i.e., clinically stable or improving state, showed positive annual rate of change in MTsat and R2* within NAWM and NACGM, suggesting repair mechanisms in terms of increased myelin content and/or axonal density as well as edema/inflammation resorption. When examining WM lesions, qMRI parameters within surrounding NAWM showed microstructural modifications, even before any focal lesion is visible on conventional FLAIR MRI. The results illustrate the benefit of multiple qMRI data in monitoring subtle changes within normal appearing brain tissues and plaque dynamics in relation with tissue repair or disease progression.

74	Keywords:
75	Quantitative MRI, relaxometry, longitudinal analysis, multiple sclerosis.
76	
77	Key points:
78	Patients with a better clinical evolution showed microstructural improvement
79	in term of MTsat and R2* increase in their normal appearing tissue, suggesting
80	repair mechanisms.
81	Using qMRI allows to detect modifications in tissue microstructure in normal
82	appearing tissues surrounding lesions several months before they are visible on
83	conventional MRI.
84	
85	

1. Introduction

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). Plaques are the pathological hallmark of MS. They are spread in acute, focal, disseminated and recurrent way throughout the CNS and harbor variable degrees of inflammation, demyelination, gliosis and axonal injury [1, 2]. Plaques are not restricted to the white matter (WM), but are also present in the cortex and deep grey matter (GM) [3-5]. Over and above focal WM lesions, an early, diffuse and chronic inflammation within the normal appearing white matter (NAWM) and grey matter (NAGM) is ultimately responsible for diffuse neuro-axonal loss and neurodegeneration, which is deemed responsible for a progressive accumulation of disability [3, 4, 6]. By contrast, effective repair mechanisms can occur within focal lesions but probably also in normal appearing brain tissue (NABT) [7]. However, our understanding of these complex processes is still fragmentary. The difficulty of acquiring histopathological data on MS patients at various stages of the disease makes it challenging to describe the time course of injury and potential repair mechanisms in MS. Consequently, there is a need for new imaging techniques to improve the in-vivo monitoring of brain damages formation, progression and repair in MS [8]. Conventional MRI (cMRI) readily depicts focal WM lesions on T2/FLAIR sequences and is able to distinguish between acute and allegedly chronic lesions. T2-hyperintensities in cMRI constitute the keystone of McDonald diagnostic criteria [9] and also make an important contribution to the monitoring of WM lesion burden. Unfortunately, cMRI sequences do not sensitively detect cortical lesions and diffuse changes in NABT, due to a rather low sensitivity of cMR imaging for cortical lesions, mixed contrast weight, and an overall limited histopathological specificity within cerebral tissues. Quantitative MRI (qMRI) potentially

overcomes these limitations by quantifying physical microstructural properties of cerebral tissue in standardized units. qMRI is more sensitive but also more specific to microstructural properties of CNS tissues. Magnetization transfer ratio (MTR) was regularly linked to cerebral macromolecular content detected by a greater percentage loss of magnetization in voxels with a higher myelin content and axons density [10-12]. Post-mortem studies comparing the relative contribution of these two factors indicate that myelin has a stronger and more direct influence on MTR than the axonal density, which is considered as a T1-dependent effect. Tissue water content (inflammation, edema...), another T1-dependent effect, also accounts for MTR variability [11, 13, 14]. However, the MT saturation (MTsat) map offers a measure which, unlike MTR, is minimally affected by longitudinal relaxation and B1 mapping inhomogeneities [15], increasing its sensitivity to myelin content. Moreover, the brain contrast to noise ratio is larger for the MTsat map than for MTR, thus improving brain tissue segmentation in healthy subjects [11, 16]. R2* was usually linked to iron and myelin contents, as paramagnetic iron and diamagnetic myelin generate microscopic field gradients in the CNS, thus shortening T2* and increasing R2* (1/T2*). Orientation and density of myelin fibers are also a determining factor of R2* values [17-19]. Iron is probably a key factor in MS monitoring as it was shown that aberrant iron metabolism occurs in the course of the disease [20]. Particularly increased iron concentration within chronic active lesions (i.e iron rim lesion) or deep grey matter structures was observed [20]. Regarding the longitudinal relaxation rate R1 (1/T1), its three major determinants in the CNS are tissue myelination and associated axons, iron, and extracellular water contents [19, 21, 22]. Finally, proton density (PD) mostly reflects the free water content of the brain [23]. A number of cross-sectional studies using a combination of MT, R1, R2* or PD parameters, comparing MS patients to healthy controls, reported significant changes in the microstructure

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

134 of NABT, such as a decrease in MT, R1 and R2* and an increase in PD in patients [24-32]. Few 135 studies addresses the longitudinal variations in qMRI. R2* [33-35], PD and T1 were reported 136 to increase in the basal ganglia over a period of a year [36], whereas a decrease in MTR in 137 NAWM was reported over one [37] or two years [38]. 138 Regarding focal WM plaques, qMRI emerges as an appealing biomarker to describe the 139 dynamic processes of demyelination and remyelination. For instance, MTR was shown to 140 sharply decrease within gadolinium enhancing lesions before recovering during the 141 subsequent months [39-41], and within NAWM days to weeks before the formation of a new 142 active lesion [42, 43]. 143 Because each qMRI parameter is differently sensitive to histologically measured iron and 144 myelin contents, this approach might become a fundamental tool for longitudinal in vivo 145 monitoring of MS lesions and NABT evolution at the tissue microstructural level. 146 In this longitudinal study, we investigate the evolution of four simultaneously acquired qMRI 147 parameters (MTsat, PD, R1, R2*) within NABT and WM lesions of 17 MS patients - relapsing 148 remitting (RRMS) and progressive MS (PMS) - who were scanned two times with at least a 149 one-year interval, following the same multi-parameter mapping (MPM) protocol at 3 Tesla 150 [10, 44]. 151 We assessed the time course of parameter values in several tissue classes: normal appearing 152 white matter (NAWM), normal appearing cortical and deep GM (NACGM and NADGM) as well 153 as focal WM lesions. In addition, we related longitudinal qMRI changes within NABT to clinical 154 course.

2. Materials and methods

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

2.1 Population

Seventeen patients, recruited at the specialized MS outpatient clinic of the CHU Liège, Belgium, with a diagnosis of MS according to the McDonald criteria 2010 [45], were gathered from two studies: ten of them were part of the work reported by Lommers et al. 2019 [24], the other seven were recruited from another MS study taking place at the GIGA Cyclotron Research Centre – In Vivo Imaging (Liège, Belgium) [46]. For the first study (10 subjects), the inclusion criteria were (1) age between 18 and 65 years; (2) Expanded Disability Status Scale (EDSS) inferior or equal to 6.5; (3) absence of relapse within the previous four weeks; (4) absence of IVMP administration for at least 6 months prior to the study. Both RRMS and PMS patients were recruited. The second study (7 subjects) differs a bit as it comprises only RRMS patients, and the inclusion criteria were (1) age between 18 and 45, (2) EDSS between 0 and 4, (3) absence of relapse for at least 6 months prior to the study, (4) disease duration was below or equal to 5 years, (5) absence of IVMP administration for at least 6 months prior to the study. For both studies, compatibility with MRI and absence of other neurological/psychiatric diseases were required. These studies were approved by the local ethics committee (approval numbers B707201213806 and B707201835630, respectively). All patients were followed up and scanned twice on the same 3T MRI scanner, every 1 to 3 years. For each of the 17 MS patients, data from two MRI sessions were available, at T0 and T1. This cohort included 11 RRMS and 6 (primary and secondary) PMS patients. Thirteen were receiving disease-modifying treatments (DMTs). The patients' median age was 36 years (range: 25-65) and the median time interval between two scans was 30 months (range: 14-61). Demographic data appears in Table 1. Extended individual information appears in Supplementary data.

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

2.2 MR image acquisition

MRI data were acquired on a 3T whole-body MRI-scanner (Magnetom Prisma, Siemens Medical Solutions, Erlangen, Germany). The whole-brain MRI acquisitions included a multiparameter mapping protocol (MPM), from which one can simultaneously estimate (semi)quantitative maps of magnetization transfer saturation (MTsat), proton density (PD), transverse relaxation (R1) and effective longitudinal relaxation (R2*). This protocol arising from an international collaborative effort [10, 44], has already been used to study brain microstructure in various conditions including normal aging [9, 44, 47], brain tumor [48], Parkinson's disease [49-51] as well as MS. It consists of three co-localized 3D multi-echo fast low angle shot (FLASH) acquisitions at 1mm³ resolution and two additional calibration sequences to correct for inhomogeneities in the RF transmit field [52, 53]. The FLASH datasets were acquired with predominantly PD, T1 and MT weighting, referred to in the following as PDw, T1w and MTw, at multiple echo times. All three had high bandwidth to minimize offresonance and chemical shift artifacts. Volumes were acquired in 176 sagittal slices using a 256x224 voxel matrix. GRAPPA parallel imaging was combined with partial Fourier acquisition to speed up acquisition time to approximately 20 min. An additional FLAIR sequence was recorded with spatial resolution 1mm³ and TR/TE/TI=5000ms/516ms/1800ms. Extra B1 field mapping images (transmit B1+ and receive B1- fields) were also acquired to reduce spatial inhomogeneities related to B1 effect. This was essential for proper quantification of T1 (or R1=1/T1) in particular. Finally, B0 field mapping images, corresponding to both magnitude images and pre-subtracted phase image, were acquired for image distortions corrections. A summary of the acquisition parameters appears in Supplementary data.

Note that these MR sequences at 3 Tesla are not sensitive to cortical lesion as described in [54, 55] although a few lesions at the cortico-subcortical border were detected. Quantification of cortical parameters is thus confounded by voxels potentially located within cortical lesions.

2.3 MR image processing

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

All data processing was performed in Matlab (The MathWorks Inc., Natick, MA, USA) using SPM12 (www.fil.ion.ucl.ac.uk/spm) and three additional dedicated SPM extensions: the Lesion Segmentation Tool (LST) version 1.2.3 (www.statisticalmodelling.de/lst.html) [56], the "quantitative MRI and in vivo histology using MRI" toolbox (hMRI, http://hmri.info) [10], and "US-with-Lesion" tool (USwL, https://github.com/CyclotronResearchCentre/USwLesion). Quantitative maps - MTsat, PD, R1 and R2* - were estimated using the hMRI toolbox. T1w, PDw and MTw images acquired at multiple echo times (TE) were extrapolated to TE=0 to increase signal-to-noise ratio and remove the otherwise remaining R2* bias [10, 24, 57]. The TE=0 extrapolated MTw, PDw and T1w images were used to calculate MT saturation, R1 and apparent signal amplitude A* maps. PD map was derived from A* map, which is proportional to proton density. All quantitative maps were corrected for inhomogeneities from local RF transmit field (B1+), and R1 quantitative maps were further corrected for imperfect RF spoiling using the strategy of Preibisch and Deichmann [58]. The receive bias field map (B1-) was used to correct PD maps for instrumental biases. The R2* map was estimated from all three multiecho series (MTw, PDw and R1w) using the ESTATICS model [57]. After generating quantitative maps using the hMRI toolbox for all sessions, spatial preprocessing involved the following steps (Figure 1): within-patient registration brought the two serial MR data sets into the individual TO space, using the longitudinal registration tool from SPM [59]. For each individual patient, a preliminary WM lesion mask was generated based on FLAIR and T1w images by the lesion growth algorithm implemented in the LST

toolbox [56], followed by manual corrections by an MS expert (EL) to remove aberrant/artefactual lesion detections [24]. The images were then segmented using the USwL toolbox, which consists of an extended version of the traditional Unified Segmentation (US) algorithm [60] and includes an additional tissue class representing the WM lesion(s). The USwith-lesion method internally generates a subject-specific extended set of tissue probability maps (TPM) [61]: an extra tissue class, based on the smoothed preliminary lesion mask warped into template space (using cost function masking during normalization [62]), is added to account for the lesion, and the original white matter prior map is updated accordingly [63]. The grey matter TPM was not updated due to a very low number of lesions present in the cortical ribbon. Multi-channel segmentation was conducted, using MTsat, PD, R1 and FLAIR images. This pipeline did not use the PD-, T1- and MT-weighted images acquired for the MPM maps construction, but the parametric maps themselves instead. In this way, voxels do not depict MR intensities but rather physical quantitative parameters. The method generated the segmented tissue classes (a posteriori tissue, including lesion, probability maps), as well as spatial warping into standard template space. The preliminary lesion mask was used as input for the first session data (at T0) then the *a posteriori* lesion map generated at this initial step served as prior to the subsequent session (at T1). Segmentation teased out the different tissue classes of interest: NAWM, NACGM and NADGM, as well as WM lesions. To analyze the microstructure within those tissue classes, a posteriori tissue maps were binarized and tissue-specific independent masks were constructed: each voxel is assigned to one single tissue class with the highest probability for that voxel (provided that this probability was above 0.2). The lesion binary mask was further cleaned for lesions <10mm³ which likely resulted from segmentation errors. Finally, binarized tissue class masks were in turn applied on the MPM maps to extract voxel values inside them.

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

2.4 Brain volume change

Volumetric changes were investigated using the USwL *a posteriori* tissue probability maps. The following measures of brain volume were computed for each session of each participant: (1) Total intra-cranial volume (TIV) = volume (NAWM + GM + CSF + lesions), (2) brain parenchymal fraction (BPF) = volume (NAWM + GM + lesions)/TIV, (3) Gray matter fraction (GMF) = volume (GM)/TIV, and (4) lesion fraction (LF) = volume (lesion)/TIV. The percentage of change between both scanning sessions was evaluated for each volumetric measurement, then annualized changes were computed by dividing these measures by scan intervals (in years). Results were directly analysed with a t-test (testing if significantly different from 0 at p < .05), but also in the same way as the normal appearing tissues MR parameters in relation to the patients' clinical status (see next section).

2.5 Analysis of normal appearing tissues

The median value of quantitative MRI parameters was extracted from the three normal appearing tissues (NAWM, NACGM and NADGM), and an individual annual rate of change (ARoC) was computed for each parameter in each tissue class, based on the initial and final values and accounting for the time interval (in years) between scans. This rate of change in qMRI parameters served as dependent variable in a general linear model testing the effect of clinical status:

$$Y = \beta_0 + \beta_1 X_{status} + \epsilon$$

Y is the ARoC for a qMRI parameter and tissue class, β 's are the regression parameters corresponding to the associated regressor (with β_0 the intercept), and ϵ the residuals. X_{status} is a binary categorical variable representing the patient's disease activity status: a status score of 1 was assigned to patients stable or improving from T0 to T1.

This patient status X_{status} was derived from one score of disease activity: NEDA-3 (No Evidence of Disease Activity [64]), a composite of three related measures of disease activity. A score of 0 was assigned in the presence of new clinical relapses (only concerning RRMS patients) and/or MRI activity (new or enlarged lesions visible on FLAIR T2 or Gadoliniumenhanced images) and/or sustained disability progression over six months based on Expanded Disability Status Scale (EDSS). For both RRMS and PMS patients, disability progression was defined as a 1.0-point increase if the EDSS score was \leq 4.0 at baseline and as a 0.5 point increased if the baseline EDSS score was > 4.0. The threshold of 4.0 was proposed in this study because it is considered as a milestone regarding ambulatory performance. NEDA-3 and was evaluated at mid- and end-scanning interval, and a final status score of 0 was given only to patients for which disease activity or progression was noted in both cases, indicating a clear progression of the disease over the whole interscan interval. The influence of several clinical measurements such as 25 FWT, 9HPT and SDMT was also considered to refine the evaluation of disease activity. However complete data were lacking for several patients. Moreover, when available, these additional clinical parameters did not modify the final X_{status} . Longitudinal clinical information allowing to derive the disease activity status for each subject appears in Table 2. Additional clinical information concerning annual relapse rate and treatment administration appears in Supplementary material. Permutation tests were employed for inferences [65]. R-squared value was tested against computed statistics after permutation of the data. For a number n of permutations, the X_{status} values were randomly shuffled (constructing a new regressor written X_{status}^{π}), tested against the unchanged response Y, and generating each time a permuted R-squared value (noted R_{π} , R_{obs} being the true R-squared value computed without permutation of the data).

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

The condition $X_{status} \neq X_{status}^{\pi}$ is verified at each permutation. After n permutations (with n = 5000 in this study), a p-value was computed based on the following formula:

$$p = \frac{\#(R_{\pi} > R_{obs})}{n+1}$$

which estimates the probability of obtaining R_{obs} under the null hypothesis that Y is not correlated to X_{status} . The null hypothesis is rejected if p < .05 FDR-corrected for multiple comparisons [66], for the 12 tests performed (3 tissue classes with 4 qMRI parameters).

Two-tailed t-tests were applied *post-hoc* on the significant results of permutation tests to compare the ARoC distribution between disease status, i.e., $X_{status}=0$ against $X_{status}=1$. Inferences were conducted at a significance level of .05.

The same pipeline was applied to the brain volumetric changes (BPF, GMF and LF) to test their correlation to the disease activity status.

2.6 Analysis of lesions and peripheral tissues

For white matter lesions analysis, we did not use ARoC but exploited directly the qMRI parameters voxel values. Importantly, with USwL segmentation, the prior lesion mask is only used in a probabilistic way and the estimated posterior lesion map, obtained using MTsat, PD, R1 and FLAIR images, typically showed more extended lesion than clinically visible on the FLAIR image alone. Therefore, we separated focal lesions detected on FLAIR images, with LST segmentation and visual inspection, from their peripheral regions detected on qMRI maps. Two different peripheral regions were considered: one for each time point (T0 and T1). Therefore, at T0, three distinct lesion-related regions were isolated:

- The lesions, as clinically defined, pertaining to hyperintensity on the conventional FLAIR MR image acquired at TO. These are referred to as 'focal FLAIR lesion'.
- The peripheral region detected on qMRI maps at T0, at the borders of (but not including)
 the focal FLAIR lesion. Those are referred to as 'initial peripheral lesion'.

321 The peripheral region, detected on qMRI maps at follow up, bordering (but not including) 322 the initial peripheral lesion, further referred to as 'later peripheral lesion'. This was 323 computed by masking out the T1 lesion mask with the T0 lesion mask. This region allows 324 us to determine whether its microstructure at TO forebodes a full-blown plaque, 325 detectable during follow up. Those sometimes appear hyperintense on FLAIR images. 326 The three areas were compared between each other and with NAWM, in order to characterize 327 them on a microstructural basis (Figure 2). For an accurate lesion-by-lesion analysis, only 328 enlarging lesions, i.e., present in the three masks, were considered for these comparisons. 329 NAWM region consisted of all white matter voxels which did not belong to any of the three 330 lesion-related regions. The four areas are not overlapping as no voxel could belong to more 331 than one class at the same time. 332 For all participants, MTsat, PD, R1 and R2* median values were extracted from each lesion 333 area, considering lesions individually (between 2 and 66 measurements per subject). Similarly, 334 the median qMRI values within NAWM were also extracted (one measurement per subject). 335 These values were extracted from T0 and T1 scans separately. Statistical analyses were 336 performed in SAS 9.4 (SAS Institute, Cary, NC). None of the qMRI parameter was normally 337 distributed, therefore we applied a log transformation on each of them prior to statistical 338 analysis. For each qMRI parameter, a separate Generalized Linear Mixed Model (GLMM) 339 tested the effect of areas (NAWM and the three lesion-related areas), and time points (TO and 340 T1), as well as their interaction (i.e., area*time), on the median qMRI parameter value, with a 341 first-order autoregressive variance/covariance model and participants as a random factor 342 (intercept). The degrees of freedom were estimated using Kenward-Roger's method. 343 Statistical significance was estimated at p < .05 after adjustment for multiple comparison 344 using Tukey's procedure.

3. Results

3.1 Volume changes

Brain parenchymal fraction (BPF) annually decreased between T0 and T1 by -0.67 \pm 1.12% (significantly different from zero; paired-sample t-tests; t(16)=2.57; p=.0204) whereas lesion fraction (LF) increased by 22.88 \pm 26.13% (t(16)=-3.70; p=.0019). GM fraction (GMF) non-significantly decreased by -0.30 \pm 1.44%.

3.2 Analysis of normal appearing tissues

As expected, changes in MTsat and R2* within normal appearing brain tissues (NABT) between T0 and T1 varied across subjects (Figure 3). PD and R1 exhibited similar behaviors, see Supplementary data.

At the group level, with the regression analysis and permutation inference, we observed that the annual rate of change (ARoC) of MTsat and R2* positively regressed with disease status as follows (Table 3): MTsat in NAWM and NACGM and R2* in NAWM significantly increased in patients who fare well ($X_{status} = 1$).

Post-hoc t-tests applied on these significant results for a clearer illustration of the difference in disease status (Figure 4) were all significant at a level of .05.

Regarding BPF and LF, their correlation to the disease activity status was not significant (Table 3), suggesting that qMRI parameters are more sensitive to subtle microstructural changes in normal appearing tissues over time than global morphological measurements

3.3 Analysis of lesion microstructure

The number of enlarging WM lesions between T0 and T1 varied from 2 to 66 across patients, for a total of 741 identified enlarging lesions among all subject, corresponding on average among patients to 63% (\pm 31%) of the amount of initial focal lesions. The number of enlarging

lesions did not significantly differ between patients' disease status groups (t(15) = .244, p =

369 .811).

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

370 GLMMs found a significant effect of areas (3 lesion regions and NAWM) for MTsat, R1, R2*

371 and PD median (MTsat: $F_3 = 35.34$, p < .0001, PD: $F_3 = 68.03$, p < .0001, R1: $F_3 = 68.03$

372 40.26, p < .0001, R2*: $F_3 = 32.32$, p < .0001). By contrast, neither time effect (T0 vs T1;

373 MTsat: $F_3 = 0.36$, p = .5481, PD: $F_3 = 1.20$, p = .2735, R1: $F_3 = 2.05$, p = .1520, R2*:

374 $F_3 = 2.86$, p = .0911), nor the area*time interaction (MTsat: $F_3 = 0.09$, p = .9671, PD:

 $F_3 = 0.14$, p = .9346, R1: $F_3 = 0.14$, p = .9331, R2*: $F_3 = 0.40$, p = .7565) were

significant, suggesting the microstructural stability of the initial lesion core. Post-hoc tests

confirmed significant differences between the four tissue areas.

At times T0 and T1, MTsat, R1 and R2* values were significantly larger in the initial peripheral lesion than FLAIR lesion, in the later peripheral lesion than the initial one, and in the NAWM than later peripheral lesion. The reverse was observed for PD. The significant difference in parameters between initial and later peripheral lesion at T0 suggests that subtle microstructural changes appear in the periphery of the initial lesion, months before their detection as focal FLAIR lesions at T1. Adjusted *p*-values appear in Figure 5. Detailed statistical results of the GLMM's appear in Supplementary data.

4. Discussion

This longitudinal study followed up volumetric data and qMRI brain metrics (MTsat, PD, R1, R2*) in 17 patients with multiple sclerosis for a median time interval of 30 months. The main results are threefold. First, the microstructure of normal appearing brain tissues changes over time and these modifications concur with, and potentially drive, clinical evolution. This critical finding suggests that repair mechanism and edema resorption can be monitored *in vivo*. Second, the microstructure within WM plaques is remarkably heterogeneous. Importantly, at

their periphery, microstructural alterations foreshadow their expansion, as detected by conventional MRI. Third, as expected, we observed a small but significant brain atrophy and lesion load increase with time.

Quantitative MRI parameter time course within NABT

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

In this study, we used a multiparameter mapping protocol that was gradually optimized and validated for multi-centric studies [67]. It provides high-resolution maps of multiple qMRI parameters from data acquired during a single scanning session of acceptable duration. A number of cross-sectional studies using a combination of MT, R1, R2* or PD parameters reported significant changes in the microstructure of NABT in MS [24-32]. By contrast, longitudinal analyses of multiparameter qMRI data are scarce. A progressive shortening of T2/T2* [68] or increase in R2* [33-35] was reported within the basal ganglia, suggesting increased of myelin and/or iron contents as well as edema resorption. Likewise, PD and T1 increased within a year, suggesting a demyelination and/or axonal loss [36]. MTR progressively decreases in NAWM of MS patients over one [37] or two years [38]. These abnormalities tend to be more pronounced in progressive phenotypes [69] and were associated to a slow, diffuse and global myelin pathology. Here, we showed that MTsat within NAWM and NACGM and R2* values within NAWM increase in clinically stable or improving patients. Because MTsat and R2* both correlate with myelin content [11, 47, 70-73], our results suggest repair mechanisms within NABT of patients who are responding to disease modifying treatments, despite the initial myelin/axonal loss and independently from WM focal lesion evolution. Such increases could also be explained by an edema/inflammation resorption, but less likely than myelin/axonal density changes since MTsat is the least dependent to water content among the four qMRI parameters. These results echo cross-sectional analyses showing that healthy controls (HC) have higher MTsat

and R2* values within the same tissue classes compared to MS patients [24]. Annual rates of change of R1 and PD within NABT were not significantly associated with the individual clinical status in this study, although R1 reduction within NABT has already been reported in cross sectional [24, 29, 30] and longitudinal [36] studies comparing MS subjects to HC.

Lesion microstructure

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

Focal inflammatory demyelinating lesions have been extensively characterized and are traditionally classified as active, chronic active (smoldering) or inactive plaques according to the presence and distribution of plaque-infiltrating macrophages/microglia [74-76]]. Focal WM pathology is a constantly evolving process including episodes of demyelination and remyelination but also accumulation of irreversible axonal damage. Age, disease duration, clinical phenotype as well as disease modifying treatment all contribute to the dynamic nature of focal WM pathology [75, 77]. This accounts for the large inter- and intra-individual heterogeneity of MS, which conventional MRI is largely unable to capture. By contrast, quantitative MRI parameters are sensitive to myelin, axonal as well as iron contents and appear as promising markers of plaque dynamics. For instance, MTR was shown to sharply decrease within gadolinium enhancing lesions before recovering during the subsequent months [39-41]. Likewise, reduction of MTR within NAWM, days to weeks before the formation of a new active lesion was also demonstrated [42, 43], and long-term MTR changes in WM plaques were observed in relation with disease progression [69, 78]. The present study broadens the quantitative characterization of plaque dynamics, in keeping with previous longitudinal studies [68, 79]. Two important findings emerge from the results. First, qMRI refines lesion segmentation, as compared to the processing based on the sole FLAIR image. In consequence, the initial lesion revealed by qMRI is typically wider that the plaque detected in FLAIR. Its periphery is characterized by a decrease in MTsat and R2* as compared to NAWM,

suggesting an incipient demyelination, reminiscent of the so-called 'periplaques' [80]. Moreover, MTsat, R2* and R1 values progressively decrease from NAWM to plaque core, suggesting a centripetal loss of myelin content. Second, plaque microstructure is altered in plaque periphery before any observable change in conventional MRI signals. This finding suggests, in keeping with neuropathological observations [75, 77, 81, 82] that subclinical ongoing inflammation and/or demyelination takes place in the periphery of an active plaque, well before it is detectable on FLAIR or T1 post-gadolinium sequences. If confirmed on larger population samples, this finding might significantly modify treatment management in MS patients.

Another plausible hypothesis explaining the progressive decrease of R2* in initial and later peripheral regions is that iron-containing macrophages could be removing iron from the lesions through perivascular drainage into the extracellular compartment. Previous neuropathological studies have reported an iron loss at the edges of a subset of MS lesions,

lesions through perivascular drainage into the extracellular compartment. Previous neuropathological studies have reported an iron loss at the edges of a subset of MS lesions, depending on their type (active, inactive, smoldering, etc.) as well as the patient's age and disease duration [83, 84]. Due to the limited sensitivity of R2* to local iron concentration as compared, for example, to the combined use of R2* and quantitative susceptibility mapping (QSM) [18], validating this theory would require additional measures which can better

Volumetric Data

describe iron dynamics in MS lesions and NAWM.

CNS atrophy occurs in all stages of MS, since the preclinical phase of the disease and progresses throughout its course, at a much higher rate than one reported in normal aging [85-88]. In this study, the annual brain percentage volume loss at the group level was 0.67%, which is in line with previous publications [89]. We also showed a significant increase in lesion fraction. Volumetric data (ARoC's) were highly variable across subjects: changes in BPF range

from -2.52 to 1.17% and LF from -0.78 to 103.06%. This variability arises from a large number of factors which do not necessarily relate to MS: age, disease duration, disease phenotype, disease modifying treatment, circadian rhythm, hydration... 88]. [87, Moreover, annual changes in brain parenchymal fraction as well as lesion fraction only partially correlated to patients' disease status, in accordance with a large amount of publications [36, 90]. This highlights the lack of specificity and sensitivity of volumetric measurements, at least at the individual level. It can appear odd that brain atrophy progresses in parallel to repair mechanisms, as suggested by qMRI parameters. However, BPF reduction is minimal, and is not significant (see Table 3) between T0 and T1. One should keep in mind that cortical atrophy is an irreversible phenomenon. Given the inter- and intra-individual heterogeneity of MS progression, it is possible that patients who have undergone neuron- axonal loss at some point in the disease might be able to remyelinize their remaining axons, hopefully through therapeutic intervention or lifestyle changes. Besides, axonal remyelination is not always effective. Here we showed that variations in MTsat and R2* correlated to the disease activity status, but our clinical evaluation based on EDSS is undoubtedly imprecise. Once again, the size and heterogeneity of our cohort limits the interpretation of such results.

Study limitation

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

As mentioned here above, the small size and heterogeneous aspect of the present dataset constitute major limitations of this study. Indeed, it is composed of only 17 patients, with a rather broad range of characteristics such as age, disease duration, disease phenotype, disease modifying treatment, etc., which are known to influence the disability state of the patient and thus their ability to put together repair mechanisms within cerebral tissues [1, 75-77, 91, 92]. In addition, the time interval between two scanning sessions varied rather widely

across patients (between 14 and 61 months), although it was brought back to an annual rate where possible. All of these parameters were imposed by standard clinical follow up. Therefore, these results should not be over-interpreted but are nevertheless promising and call for a replication with a larger and more homogeneous or controlled set of MS patients. Larger longitudinal studies are currently being held and will probably confirm these preliminary results. A second limitation is the absence of longitudinal MRI data acquired in a control group of healthy subjects. However, we considered that literature of longitudinal studies of healthy subjects that analysed tissue microstructure could constitute a solution for comparison with MS patients. For example, in Bonnier et al. (2017) [68], the control group did not show any significant differences regarding T1, T2* or MTR measurements over two years, and the median age of their group is quite similar to ours (34,3 vs 36 years). Also, in Elkady et al. (2018) [33], they found no longitudinal R2* effect in their control groups, even with an age range superior to ours. Moreover, the median age of our population (< 60 years), as well as the short period between two scanning sessions (median of 14 months), suggests that microstructural alterations would not be noticeable in a healthy participants group, as many

5. Conclusion

These preliminary results highlight the relevance of multiple qMRI data in the monitoring of MS disease, highlighting subtle changes within NABT and plaque dynamics in relation with repair or disease progression. Of course, large scale longitudinal study would be needed to reproduce these findings and better exploit the full potential of qMRI parameters.

quantitative ageing studies detected differences over much larger time periods [44, 70, 93].

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

511 References 512 [1] Lassmann, Hans. "Pathology and Disease Mechanisms in Different Stages of Multiple 513 Sclerosis." Journal of the Neurological Sciences 333, no. 1–2 (October 2013): 1–4. 514 https://doi.org/10.1016/j.jns.2013.05.010. 515 516 [2] Trapp, Bruce D., John Peterson, Richard M. Ransohoff, Richard Rudick, Sverre Mörk, and 517 Lars Bö. "Axonal Transection in the Lesions of Multiple Sclerosis." New England Journal of 518 Medicine 338, no. 5 (January 29, 1998): 278-85. 519 https://doi.org/10.1056/NEJM199801293380502. 520 521 [3] Haider, Lukas, Tobias Zrzavy, Simon Hametner, Romana Höftberger, Francesca Bagnato, 522 Günther Grabner, Siegfried Trattnig, Sabine Pfeifenbring, Wolfgang Brück, and Hans 523 Lassmann. "The Topograpy of Demyelination and Neurodegeneration in the Multiple Sclerosis 524 Brain." Brain 139, no. 3 (March 2016): 807–15. https://doi.org/10.1093/brain/awv398. 525 [4] Kutzelnigg, Alexandra, Claudia F. Lucchinetti, Christine Stadelmann, Wolfgang Brück, 526 527 Helmut Rauschka, Markus Bergmann, Manfred Schmidbauer, Joseph E. Parisi, and Hans 528 Lassmann. "Cortical Demyelination and Diffuse White Matter Injury in Multiple Sclerosis." 529 Brain 128, no. 11 (November 1, 2005): 2705–12. https://doi.org/10.1093/brain/awh641. 530 531 [5] Gh Popescu, Bogdan F, and Claudia F Lucchinetti. "Meningeal and Cortical Grey Matter 532 Pathology in Multiple Sclerosis." BMC Neurology 12, no. 1 (December 2012): 11. 533 https://doi.org/10.1186/1471-2377-12-11.

536 Rauschka, Manfred Schmidbauer, Henning Laursen, Per Soelberg Sorensen, and Hans 537 Lassmann. "The Relation between Inflammation and Neurodegeneration in Multiple Sclerosis 538 Brains." Brain 132, no. 5 (May 2009): 1175-89. https://doi.org/10.1093/brain/awp070. 539 540 [7] Brown, Robert A., Sridar Narayanan, and Douglas L. Arnold. "Imaging of Repeated Episodes 541 of Demyelination and Remyelination in Multiple Sclerosis." NeuroImage: Clinical 6 (2014): 20-542 25. https://doi.org/10.1016/j.nicl.2014.06.009. 543 544 [8] Wang, Chenyu Tim, Michael Barnett, and Yael Barnett. "Imaging the Multiple Sclerosis 545 Lesion: Insights into Pathogenesis, Progression and Repair." Current Opinion in Neurology 32, 546 no. 3 (June 2019): 338-45. https://doi.org/10.1097/WCO.0000000000000698. 547 548 [9] Thompson, Alan J, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, 549 Giancarlo Comi, Jorge Correale, et al. "Diagnosis of Multiple Sclerosis: 2017 Revisions of the 550 McDonald Criteria." The Lancet Neurology 17, no. 2 (February 2018): 162-73. 551 https://doi.org/10.1016/S1474-4422(17)30470-2. 552 553 [10] Tabelow, Karsten, Evelyne Balteau, John Ashburner, Martina F. Callaghan, Bogdan 554 Draganski, Gunther Helms, Ferath Kherif, et al. "HMRI – A Toolbox for Quantitative MRI in 555 Neuroscience and Clinical Research." NeuroImage 194 (July 2019): 191–210. 556 https://doi.org/10.1016/j.neuroimage.2019.01.029.

[6] Frischer, Josa M., Stephan Bramow, Assunta Dal-Bianco, Claudia F. Lucchinetti, Helmut

535

- 558 [11] Schmierer, Klaus, Francesco Scaravilli, Daniel R. Altmann, Gareth J. Barker, and David H.
- 559 Miller. "Magnetization Transfer Ratio and Myelin in Postmortem Multiple Sclerosis Brain."
- 560 Annals of Neurology 56, no. 3 (September 2004): 407–15. https://doi.org/10.1002/ana.20202.

- [12] Callaghan, Martina F., Gunther Helms, Antoine Lutti, Siawoosh Mohammadi, and Nikolaus
- Weiskopf. "A General Linear Relaxometry Model of R 1 Using Imaging Data: General Linear
- Relaxometry Model of R1." Magnetic Resonance in Medicine 73, no. 3 (March 2015): 1309–
- 565 14. https://doi.org/10.1002/mrm.25210.

566

- [13] Van Waesberghe, J. H. T. M., W. Kamphorst, C. J. A. De Groot, M. A. A. Van Walderveen,
- J. A. Castelijns, R. Ravid, G. J. Lycklama a Nijeholt, et al. "Axonal Loss in Multiple Sclerosis
- Lesions: Magnetic Resonance Imaging Insights into Substrates of Disability." Annals of
- 570 Neurology 46, no. 5 (November 1999): 747–54. https://doi.org/10.1002/1531-
- 571 <u>8249(199911)46:5<747::AID-ANA10>3.0.CO;2-4.</u>

572

- [14] Mottershead, J. P., K. Schmierer, M. Clemence, J. S. Thornton, F. Scaravilli, G. J. Barker, P.
- 574 S. Tofts, et al. "High Field MRI Correlates of Myelin Content and Axonal Density in Multiple
- 575 Sclerosis." *Journal of Neurology* 250, no. 11 (November 1, 2003): 1293–1301.
- 576 https://doi.org/10.1007/s00415-003-0192-3.

- 578 [15] Lema, Alfonso, Courtney Bishop, Omar Malik, Miriam Mattoscio, Rehiana Ali, Richard
- Nicholas, Paolo A. Muraro, Paul M. Matthews, Adam D. Waldman, and Rexford D. Newbould.
- 580 "A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord

581 Microstructure in Multiple Sclerosis: MT of Brain and c-Spine in MS." Journal of Neuroimaging 582 27, no. 2 (March 2017): 221–26. https://doi.org/10.1111/jon.12377. 583 584 [16] Helms, Gunther, Henning Dathe, and Peter Dechent. "Modeling the Influence of TR and 585 Excitation Flip Angle on the Magnetization Transfer Ratio (MTR) in Human Brain Obtained 586 from 3D Spoiled Gradient Echo MRI." Magnetic Resonance in Medicine 64, no. 1 (July 2010): 587 177-85. https://doi.org/10.1002/mrm.22379. 588 589 [17] Bagnato, Francesca, Simon Hametner, Emma Boyd, Verena Endmayr, Yaping Shi, Vasiliki 590 Ikonomidou, Guanhua Chen, et al. "Untangling the R2* Contrast in Multiple Sclerosis: A 591 Combined MRI-Histology Study at 7.0 Tesla." Edited by Quan Jiang. PLOS ONE 13, no. 3 (March 592 21, 2018): e0193839. https://doi.org/10.1371/journal.pone.0193839. 593 594 [18] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max Prihoda, Evelin 595 Haimburger, Christian Menard, et al. "The Influence of Brain Iron and Myelin on Magnetic 596 Susceptibility and Effective Transverse Relaxation - A Biochemical and Histological Validation 597 Study." NeuroImage 179 (October 2018): 117-33. 598 https://doi.org/10.1016/j.neuroimage.2018.06.007. 599 600 [19] Stüber, Carsten, Markus Morawski, Andreas Schäfer, Christian Labadie, Miriam Wähnert, 601 Christoph Leuze, Markus Streicher, et al. "Myelin and Iron Concentration in the Human Brain: 602 A Quantitative Study of MRI Contrast." NeuroImage 93 (June 2014): 95–106. 603 https://doi.org/10.1016/j.neuroimage.2014.02.026.

605 [20] Stankiewicz, James M., Mohit Neema, et Antonia Ceccarelli. « Iron and Multiple 606 Sclerosis ». Neurobiology of Aging 35 (September 2014): S51-58. 607 https://doi.org/10.1016/j.neurobiolaging.2014.03.039. 608 609 [21] Granziera, Cristina, Jens Wuerfel, Frederik Barkhof, Massimiliano Calabrese, Nicola De 610 Stefano, Christian Enzinger, Nikos Evangelou, et al. "Quantitative Magnetic Resonance 611 Imaging towards Clinical Application in Multiple Sclerosis." Brain 144, no. 5 (June 22, 2021): 612 1296-1311. https://doi.org/10.1093/brain/awab029. 613 614 [22] Kolb, Hadar, Martina Absinta, Erin S. Beck, Seung-Kwon Ha, Yeajin Song, Gina Norato, 615 Irene Cortese, Pascal Sati, Govind Nair, and Daniel S. Reich. "7T MRI Differentiates 616 Remyelinated from Demyelinated Multiple Sclerosis Lesions." Annals of Neurology 90, no. 4 617 (October 2021): 612-26. https://doi.org/10.1002/ana.26194. 618 619 [23] Edwards, Luke J., Evgeniya Kirilina, Siawoosh Mohammadi, and Nikolaus Weiskopf. 620 "Microstructural Imaging of Human Neocortex in Vivo." NeuroImage 182 (November 2018): 621 184–206. https://doi.org/10.1016/j.neuroimage.2018.02.055. 622 623 [24] Lommers, Emilie, Jessica Simon, Gilles Reuter, Gaël Delrue, Dominique Dive, Christian 624 Degueldre, Evelyne Balteau, Christophe Phillips, and Pierre Maquet. "Multiparameter MRI

Quantification of Microstructural Tissue Alterations in Multiple Sclerosis." NeuroImage:

Clinical 23 (2019): 101879. https://doi.org/10.1016/j.nicl.2019.101879.

625

626

628 [25] Lommers, Emilie, Camille Guillemin, Gilles Reuter, Eve Fouarge, Gaël Delrue, Fabienne 629 Collette, Christian Degueldre, Evelyne Balteau, Pierre Maquet, and Christophe Phillips. "Voxel-BASED Quantitative MRI Reveals Spatial Patterns of Grey Matter Alteration in Multiple 630 631 Sclerosis." Human Brain Mapping (March 2021): 1003-12. 42, no. 632 https://doi.org/10.1002/hbm.25274. 633 634 [26] Andica, Christina, Akifumi Hagiwara, Koji Kamagata, Kazumasa Yokoyama, Keigo Shimoji, 635 Asami Saito, Yuki Takenaka, et al. "Gray Matter Alterations in Early and Late Relapsing-636 Remitting Multiple Sclerosis Evaluated with Synthetic Quantitative Magnetic Resonance 637 Imaging." Scientific Reports 9, no. 1 (December 2019): 8147. https://doi.org/10.1038/s41598-638 <u>019-44615-3</u>. 639 640 [27] Bonnier, Guillaume, Alexis Roche, David Romascano, Samanta Simioni, Djalel Meskaldji, 641 David Rotzinger, Ying-Chia Lin, et al. "Advanced MRI Unravels the Nature of Tissue Alterations 642 in Early Multiple Sclerosis." Annals of Clinical and Translational Neurology 1, no. 6 (June 2014): 643 423-32. https://doi.org/10.1002/acn3.68. 644 645 [28] Engström, Maria, Jan B. M. Warntjes, Anders Tisell, Anne-Marie Landtblom, and Peter Lundberg. "Multi-Parametric Representation of Voxel-Based Quantitative Magnetic 646 Resonance Imaging." Edited by Friedemann Paul. PLoS ONE 9, no. 11 (November 13, 2014): 647 648 e111688. https://doi.org/10.1371/journal.pone.0111688. 649 650 [29] Gracien, René-Maxime, Alina Jurcoane, Marlies Wagner, Sarah C. Reitz, Christoph Mayer, 651 Steffen Volz, Stephanie-Michelle Hof, et al. "Multimodal Quantitative MRI Assessment of 652 Cortical Damage in Relapsing-Remitting Multiple Sclerosis: Cortical Quantitative MRI in 653 RRMS." Journal of Magnetic Resonance Imaging 44, no. 6 (December 2016): 1600–1607. https://doi.org/10.1002/jmri.25297. 654 655 656 [30] Neema, Mohit, James Stankiewicz, Ashish Arora, Venkata S.R. Dandamudi, Courtney E. 657 Batt, Zachary D. Guss, Ali Al-Sabbagh, and Rohit Bakshi. "T1- and T2-Based MRI Measures of 658 Diffuse Gray Matter and White Matter Damage in Patients with Multiple Sclerosis." Journal of 659 *Neuroimaging* 17 (April 2007): 16S-21S. https://doi.org/10.1111/j.1552-6569.2007.00131.x. 660 661 [31] Reitz, Sarah C., Stephanie-Michelle Hof, Vinzenz Fleischer, Alla Brodski, Adriane Gröger, 662 René-Maxime Gracien, Amgad Droby, et al. "Multi-Parametric Quantitative MRI of Normal 663 Appearing White Matter in Multiple Sclerosis, and the Effect of Disease Activity on T2." Brain 664 Imaging and Behavior 11, no. 3 (June 2017): 744-53. https://doi.org/10.1007/s11682-016-665 <u>9550-5</u>. 666 667 [32] Stevenson, V.L, G.J.M Parker, G.J Barker, K Birnie, P.S Tofts, D.H Miller, and A.J Thompson. 668 "Variations in T1 and T2 Relaxation Times of Normal Appearing White Matter and Lesions in 669 Multiple Sclerosis." Journal of the Neurological Sciences 178, no. 2 (September 2000): 81–87. 670 https://doi.org/10.1016/S0022-510X(00)00339-7. 671 672 [33] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Gregg Blevins, and Alan H. Wilman. 673 "Discriminative Analysis of Regional Evolution of Iron and Myelin/Calcium in Deep Gray Matter 674 of Multiple Sclerosis and Healthy Subjects: Analysis of Iron and Myelin in MS." Journal of

- 675 Magnetic Resonance Imaging 48, no. 3 (September 2018): 652-68.
- 676 https://doi.org/10.1002/jmri.26004.

- 678 [34] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Peter Seres, Gregg Blevins, and Alan H.
- 679 Wilman. "Five Year Iron Changes in Relapsing-Remitting Multiple Sclerosis Deep Gray Matter
- 680 Compared to Healthy Controls." Multiple Sclerosis and Related Disorders 33 (August 2019):
- 681 107–15. https://doi.org/10.1016/j.msard.2019.05.028.

682

- [35] Khalil, M., C. Langkammer, A. Pichler, D. Pinter, T. Gattringer, G. Bachmaier, S. Ropele, S.
- 684 Fuchs, C. Enzinger, and F. Fazekas. "Dynamics of Brain Iron Levels in Multiple Sclerosis: A
- 685 Longitudinal 3T MRI Study." *Neurology* 84, no. 24 (June 16, 2015): 2396–2402.
- 686 https://doi.org/10.1212/WNL.000000000001679.

687

- 688 [36] Gracien, René-Maxime, Sarah C. Reitz, Stephanie-Michelle Hof, Vinzenz Fleischer, Amgad
- Droby, Mathias Wahl, Helmuth Steinmetz, Sergiu Groppa, Ralf Deichmann, and Johannes C.
- 690 Klein. "Longitudinal Quantitative MRI Assessment of Cortical Damage in Multiple Sclerosis: A
- 691 Pilot Study: Longitudinal Cortical QMRI in MS." Journal of Magnetic Resonance Imaging 46,
- 692 no. 5 (November 2017): 1485–90. https://doi.org/10.1002/jmri.25685.

693

- 694 [37] Laule, Cornelia, I. M. Vavasour, K. P. Whittall, J. Oger, D. W. Paty, D. K. B. Li, A. L. MacKay,
- and D. L. Arnold. "Evolution of Focal and Diffuse magnetisation Transfer Abnormalities in
- 696 Multiple Sclerosis." Journal of Neurology 250, no. 8 (August 2003): 924-31.
- 697 https://doi.org/10.1007/s00415-003-1115-z.

- 699 [38] Hayton, T., J. Furby, K. J. Smith, D. R. Altmann, R. Brenner, J. Chataway, K. Hunter, D. J.
- 700 Tozer, D. H. Miller, and R. Kapoor. "Longitudinal Changes in Magnetisation Transfer Ratio in
- 701 Secondary Progressive Multiple Sclerosis: Data from a Randomised Placebo Controlled Trial of
- 702 Lamotrigine." Journal of Neurology 259, no. 3 (March 2012): 505–14.
- 703 https://doi.org/10.1007/s00415-011-6212-9.

- 705 [39] Dousset, Vincent, Annick Gayou, Bruno Brochet, and Jean-Marie Caille. "Early Structural
- 706 Changes in Acute MS Lesions Assessed by Serial Magnetization Transfer Studies." Neurology
- 707 51, no. 4 (October 1998): 1150–55. https://doi.org/10.1212/WNL.51.4.1150.

708

- 709 [40] Levesque, Ives R., Paul S. Giacomini, Sridar Narayanan, Luciana T. Ribeiro, John G. Sled,
- 710 Doug L. Arnold, and G. Bruce Pike. "Quantitative Magnetization Transfer and Myelin Water
- 711 Imaging of the Evolution of Acute Multiple Sclerosis Lesions: Quantitative MT and T 2 in Acute
- 712 MS Lesions." Magnetic Resonance in Medicine 63, no. 3 (March 2010): 633–40.
- 713 https://doi.org/10.1002/mrm.22244.

714

- 715 [41] Elskamp, Ij van den, Dl Knol, H. Vrenken, G. Karas, A. Meijerman, M. Filippi, L. Kappos, et
- al. "Lesional Magnetization Transfer Ratio: A Feasible Outcome for Remyelinating Treatment
- 717 Trials in Multiple Sclerosis." Multiple Sclerosis Journal 16, no. 6 (June 2010): 660–69.
- 718 https://doi.org/10.1177/1352458510364630.

- 720 [42] Filippi, Massimo, Maria A. Rocca, Gianvito Martino, Mark A. Horsfield, and Giancarlo
- 721 Comi. "Magnetization Transfer Changes in the Normal Appering White Matter Precede the

- Appearance of Enhancing Lesions in Patients with Multiple Sclerosis." Annals of Neurology 43,
- 723 no. 6 (June 1998): 809–14. https://doi.org/10.1002/ana.410430616.

- 725 [43] Fazekas, F, S Ropele, C Enzinger, T Seifert, and S Strasser-Fuchs. "Quantitative
- 726 Magnetization Transfer Imaging of Pre-Lesional White-Matter Changes in Multiple Sclerosis."
- 727 Multiple Sclerosis Journal 8, no. 6 (December 2002): 479–84.
- 728 <u>https://doi.org/10.1191/1352458502ms860oa</u>.

729

- 730 [44] Draganski, B., J. Ashburner, C. Hutton, F. Kherif, R.S.J. Frackowiak, G. Helms, and N.
- 731 Weiskopf. "Regional Specificity of MRI Contrast Parameter Changes in Normal Ageing
- Revealed by Voxel-Based Quantification (VBQ)." NeuroImage 55, no. 4 (April 2011): 1423–34.
- 733 <u>https://doi.org/10.1016/j.neuroimage.2011.01.052</u>.

734

- 735 [45] Polman, Chris H., Stephen C. Reingold, Brenda Banwell, Michel Clanet, Jeffrey A. Cohen,
- 736 Massimo Filippi, Kazuo Fujihara, et al. "Diagnostic Criteria for Multiple Sclerosis: 2010
- Revisions to the McDonald Criteria." *Annals of Neurology* 69, no. 2 (February 2011): 292–302.
- 738 https://doi.org/10.1002/ana.22366.

739

- 740 [46] Guillemin, C., E. Lommers, G. Delrue, E. Gester, P. Maquet, et F. Collette. « The Complex
- 741 Interplay Between Trait Fatigue and Cognition in Multiple Sclerosis ». Psychologica Belgica 62,
- 742 nº 1 (March 2022): 108. https://doi.org/10.5334/pb.1125.

743

745	[47] Carey, Daniel, Francesco Caprini, Micah Allen, Antoine Lutti, Nikolaus Weiskopf, Gerain
746	Rees, Martina F. Callaghan, and Frederic Dick. "Quantitative MRI Provides Markers of Intra-
747	Inter-Regional, and Age-Related Differences in Young Adult Cortical Microstructure.
748	<i>NeuroImage</i> 182 (November 2018): 429–40
749	https://doi.org/10.1016/j.neuroimage.2017.11.066.
750	
751	[48] Reuter, Gilles, Emilie Lommers, Evelyne Balteau, Jessica Simon, Christophe Phillips, Felix
752	Scholtes, Didier Martin, Arnaud Lombard, and Pierre Maquet. "Multiparameter Quantitative
753	Histological MRI Values in High-Grade Gliomas: A Potential Biomarker of Tumor Progression.
754	Neuro-Oncology Practice 7, no. 6 (December 4, 2020): 646–55
755	https://doi.org/10.1093/nop/npaa047.
756	
757	[49] Depierreux, Frédérique, Eric Parmentier, Laurane Mackels, Katherine Baquero, Christian
758	Degueldre, Evelyne Balteau, Eric Salmon, et al. "Parkinson's Disease Multimodal Imaging: F
759	DOPA PET, Neuromelanin-Sensitive and Quantitative Iron-Sensitive MRI." Npj Parkinson's
760	Disease 7, no. 1 (December 2021): 57. https://doi.org/10.1038/s41531-021-00199-2 .
761	
762	[50] Nürnberger, Lucas, René-Maxime Gracien, Pavel Hok, Stephanie-Michelle Hof, Udo Rüb
763	Helmuth Steinmetz, Rüdiger Hilker, Johannes C. Klein, Ralf Deichmann, and Simon Baudrexel
764	"Longitudinal Changes of Cortical Microstructure in Parkinson's Disease Assessed with Ta
765	Relaxometry." NeuroImage: Clinical 13 (2017): 405–14
766	https://doi.org/10.1016/j.nicl.2016.12.025.

- 768 [51] Klein, J.C., M. Rolinski, L. Griffanti, K. Szewczyk-Krolikowski, F. Baig, C. Ruffmann, A.R.
- Groves, R.A.L. Menke, M.T. Hu, and C. Mackay. "Cortical Structural Involvement and Cognitive
- 770 Dysfunction in Early Parkinson's Disease." *NMR in Biomedicine* 31, no. 4 (April 2018): e3900.
- 771 https://doi.org/10.1002/nbm.3900.

- 773 [52] Lutti, Antoine, Chloe Hutton, Jürgen Finsterbusch, Gunther Helms, and Nikolaus
- 774 Weiskopf. "Optimization and Validation of Methods for Mapping of the Radiofrequency
- 775 Transmit Field at 3T: Optimized RF Transmit Field Mapping at 3T." Magnetic Resonance in
- 776 *Medicine* 64, no. 1 (July 2010): 229–38. https://doi.org/10.1002/mrm.22421.

777

- 778 [53] Lutti, Antoine, Joerg Stadler, Oliver Josephs, Christian Windischberger, Oliver Speck,
- Johannes Bernarding, Chloe Hutton, and Nikolaus Weiskopf. "Robust and Fast Whole Brain
- 780 Mapping of the RF Transmit Field B1 at 7T." Edited by Wang Zhan. *PLoS ONE* 7, no. 3 (March
- 781 12, 2012): e32379. https://doi.org/10.1371/journal.pone.0032379.

782

- 783 [54] Filippi, M., Rocca, M. A., Horsfield, M. A., Hametner, S., Geurts, J. J., Comi, G., & Lassmann,
- 784 H. "Imaging cortical damage and dysfunction in multiple sclerosis." *JAMA neurology*, 70(5)
- 785 (May 2013): 556–564. https://doi.org/10.1001/jamaneurol.2013.1954

786

- 787 [55] Hulst, Hanneke E, and Jeroen JG Geurts. "Gray Matter Imaging in Multiple Sclerosis: What
- 788 Have We Learned?" BMC Neurology 11, no. 1 (December 2011): 153.
- 789 https://doi.org/10.1186/1471-2377-11-153.

790

- 792 [56] Schmidt, Paul, Christian Gaser, Milan Arsic, Dorothea Buck, Annette Förschler, Achim
- 793 Berthele, Muna Hoshi, et al. "An Automated Tool for Detection of FLAIR-Hyperintense White-
- 794 Matter Lesions in Multiple Sclerosis." *NeuroImage* 59, no. 4 (February 2012): 3774–83.
- 795 https://doi.org/10.1016/j.neuroimage.2011.11.032.

- 797 [57] Weiskopf, Nikolaus, Martina F. Callaghan, Oliver Josephs, Antoine Lutti, and Siawoosh
- 798 Mohammadi. "Estimating the Apparent Transverse Relaxation Time (R2*) from Images with
- 799 Different Contrasts (ESTATICS) Reduces Motion Artifacts." Frontiers in Neuroscience 8
- 800 (September 10, 2014). https://doi.org/10.3389/fnins.2014.00278.

801

- 802 [58] Preibisch, C., and R. Deichmann. "Influence of RF Spoiling on the Stability and Accuracy of
- 7_1 Mapping Based on Spoiled FLASH with Varying Flip Angles: Influence of RF Spoiling on T_1
- 804 Mapping." Magnetic Resonance in Medicine 61, no. 1 (January 2009): 125–35.
- 805 <u>https://doi.org/10.1002/mrm.21776</u>.

806

- 807 [59] Ashburner, John. "Symmetric Diffeomorphic Modeling of Longitudinal Structural MRI."
- 808 Frontiers in Neuroscience 6 (2013). https://doi.org/10.3389/fnins.2012.00197.

809

- [60] Ashburner, John, and Karl J. Friston. "Unified Segmentation." NeuroImage 26, no. 3 (July
- 811 2005): 839–51. https://doi.org/10.1016/j.neuroimage.2005.02.018.

- 813 [61] Lorio, S., S. Fresard, S. Adaszewski, F. Kherif, R. Chowdhury, R.S. Frackowiak, J. Ashburner,
- 814 et al. "New Tissue Priors for Improved Automated Classification of Subcortical Brain Structures

815 on MRI." Neurolmage 130 (April 2016): 157-66. 816 https://doi.org/10.1016/j.neuroimage.2016.01.062. 817 818 [62] Andersen, Sarah M., Steven Z. Rapcsak, and Pélagie M. Beeson. "Cost Function Masking 819 during Normalization of Brains with Focal Lesions: Still a Necessity?" NeuroImage 53, no. 1 820 (October 2010): 78–84. https://doi.org/10.1016/j.neuroimage.2010.06.003. 821 822 [63] Moon, Nathan, Elizabeth Bullitt, Koen van Leemput, and Guido Gerig. "Automatic Brain 823 and Tumor Segmentation." In Medical Image Computing and Computer-Assisted Intervention 824 - MICCAI 2002, edited by Takeyoshi Dohi and Ron Kikinis, 2488:372-79. Lecture Notes in 825 Computer Science. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. 826 https://doi.org/10.1007/3-540-45786-0 46. 827 828 [64] Pandit, Lekha. "No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the 829 Goal Posts." Annals of Indian Academy of Neurology 22, no. 3 (2019): 261. 830 https://doi.org/10.4103/aian.AIAN 159 19. 831 832 [65] Anderson, Marti J. "Permutation Tests for Univariate or Multivariate Analysis of Variance 833 and Regression." Canadian Journal of Fisheries and Aquatic Sciences 58, no. 3 (March 1, 2001): 834 626-39. https://doi.org/10.1139/f01-004. 835 836 [66] Yoav Benjamini and Yosef Hochberg. "Controlling the False Discovery Rate: a Practical and 837 Powerful Approach to Multiple Testing" Journal of the Royal Statistical Society. Series B 838 (Methodological), Vol. 57, No.1 (1995), 289-300.

[67] Leutritz, Tobias, Maryam Seif, Gunther Helms, Rebecca S Samson, Armin Curt, Patrick Freund, and Nikolaus Weiskopf. "Multiparameter Mapping of Relaxation (R1, R2*), Proton Density and Magnetization Transfer Saturation at 3 T: A Multicenter Dual-vendor Reproducibility and Repeatability Study." *Human Brain Mapping* 41, no. 15 (October 15,

2020): 4232-47. https://doi.org/10.1002/hbm.25122.

[68] Bonnier, Guillaume, Benedicte Maréchal, Mário João Fartaria, Pavel Falkowskiy, José P. Marques, Samanta Simioni, Myriam Schluep, et al. "The Combined Quantification and Interpretation of Multiple Quantitative Magnetic Resonance Imaging Metrics Enlightens Longitudinal Changes Compatible with Brain Repair in Relapsing-Remitting Multiple Sclerosis Patients." *Frontiers in Neurology* 8 (September 27, 2017): 506. https://doi.org/10.3389/fneur.2017.00506.

[69] Rocca, Maria A, Giovanna Mastronardo, Mariemma Rodegher, Giancarlo Comi, and Massimo Filippi. "Long-Term Changes of Magnetization Transfer-Derived Measures from Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis," *AJNR Am J Neuroradiol* 20 (1999):821–827

[70] Callaghan, Martina F., Patrick Freund, Bogdan Draganski, Elaine Anderson, Marinella Cappelletti, Rumana Chowdhury, Joern Diedrichsen, et al. "Widespread Age-Related Differences in the Human Brain Microstructure Revealed by Quantitative Magnetic Resonance Imaging." *Neurobiology of Aging* 35, no. 8 (August 2014): 1862–72.

https://doi.org/10.1016/j.neurobiolaging.2014.02.008.

- 864 [71] Weiskopf, Nikolaus, Siawoosh Mohammadi, Antoine Lutti, and Martina F. Callaghan.
- 865 "Advances in MRI-Based Computational Neuroanatomy: From Morphometry to in-Vivo
- 866 Histology." Current Opinion in Neurology 28, no. 4 (August 2015): 313-22.
- 867 https://doi.org/10.1097/WCO.000000000000222.

- [72] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max Prihoda, Evelin
- Haimburger, Christian Menard, et al. "The Influence of Brain Iron and Myelin on Magnetic
- 871 Susceptibility and Effective Transverse Relaxation A Biochemical and Histological Validation
- 872 Study." *NeuroImage* 179 (October 2018): 117–33.
- 873 https://doi.org/10.1016/j.neuroimage.2018.06.007.

874

- 875 [73] Mangeat, G., S.T. Govindarajan, C. Mainero, and J. Cohen-Adad. "Multivariate
- 876 Combination of Magnetization Transfer, T 2 * and B0 Orientation to Study the Myelo-
- 877 Architecture of the in Vivo Human Cortex." NeuroImage 119 (October 2015): 89–102.
- 878 https://doi.org/10.1016/j.neuroimage.2015.06.033.

879

- [74] Dutta, R., and B. D. Trapp. "Pathogenesis of Axonal and Neuronal Damage in Multiple
- 881 Sclerosis." Neurology 68, no. Issue 22, Supplement 3 (May 29, 2007): S22-31.
- 882 https://doi.org/10.1212/01.wnl.0000275229.13012.32.

- 884 [75] Frischer, Josa M., Stephen D. Weigand, Yong Guo, Nilufer Kale, Joseph E. Parisi, Istvan
- Pirko, Jay Mandrekar, et al. "Clinical and Pathological Insights into the Dynamic Nature of the

White Matter Multiple Sclerosis Plaque: Dynamic Nature of MS Plaque." Annals of Neurology 886 887 78, no. 5 (November 2015): 710–21. https://doi.org/10.1002/ana.24497. 888 889 [76] Lassmann, Hans, Wolfgang Brück, and Claudia Lucchinetti. "Heterogeneity of Multiple 890 Sclerosis Pathogenesis: Implications for Diagnosis and Therapy." Trends in Molecular Medicine 891 7, no. 3 (March 2001): 115-21. https://doi.org/10.1016/S1471-4914(00)01909-2. 892 893 [77] Lucchinetti, Claudia, Wolfgang Brück, Joseph Parisi, Bernd Scheithauer, Moses Rodriguez, 894 and Hans Lassmann. "Heterogeneity of Multiple Sclerosis Lesions: Implications for the 895 Pathogenesis of Demyelination." Annals of Neurology 47, no. 6 (June 2000): 707-17. 896 https://doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q. 897 898 [78] Zheng, Yufan, Jar-Chi Lee, Richard Rudick, and Elizabeth Fisher. "Long-Term 899 Magnetization Transfer Ratio Evolution in Multiple Sclerosis White Matter Lesions: Long-Term 900 MTR Evolution in MS WM Lesions." Journal of Neuroimaging 28, no. 2 (March 2018): 191–98. 901 https://doi.org/10.1111/jon.12480. 902 903 [79] Chawla, Sanjeev, Ilya Kister, Tim Sinnecker, Jens Wuerfel, Jean-Christophe Brisset, 904 Friedemann Paul, and Yulin Ge. "Longitudinal Study of Multiple Sclerosis Lesions Using Ultra-905 High Field (7T) Multiparametric MR Imaging." Edited by Quan Jiang. PLOS ONE 13, no. 9 (September 13, 2018): e0202918. https://doi.org/10.1371/journal.pone.0202918. 906 907 908 [80] Lieury, Alice, Marie Chanal, Géraldine Androdias, Richard Reynolds, Sylvie Cavagna, Pascale Giraudon, Christian Confavreux, and Serge Nataf. "Tissue Remodeling in Periplaque 909

910 Regions of Multiple Sclerosis Spinal Cord Lesions: Glia Remodeling in MS Spinal Cord." Glia 62, 911 no. 10 (October 2014): 1645–58. https://doi.org/10.1002/glia.22705. 912 913 [81] Kuhlmann, Tanja, Samuel Ludwin, Alexandre Prat, Jack Antel, Wolfgang Brück, and Hans 914 Lassmann. "An Updated Histological Classification System for Multiple Sclerosis Lesions." Acta 915 Neuropathologica 133, no. 1 (January 2017): 13-24. https://doi.org/10.1007/s00401-016-916 1653-y. 917 918 [82] Lassmann, Hans, Wolfgang Brück, and Claudia F. Lucchinetti. "The Immunopathology of 919 Multiple Sclerosis: An Overview." Brain Pathology 17, no. 2 (April 2007): 210-18. 920 https://doi.org/10.1111/j.1750-3639.2007.00064.x. 921 922 [83] Hametner, Simon, Isabella Wimmer, Lukas Haider, Sabine Pfeifenbring, Wolfgang Brück, 923 and Hans Lassmann. "Iron and Neurodegeneration in the Multiple Sclerosis Brain." Annals of 924 Neurology 74, no. 6 (December 2013): 848-61. https://doi.org/10.1002/ana.23974. 925 926 [84] Popescu, Bogdan F., Josa M. Frischer, Samuel M. Webb, Mylyne Tham, Reginald C. Adiele, 927 Christopher A. Robinson, Patrick D. Fitz-Gibbon, et al. "Pathogenic Implications of Distinct 928 Patterns of Iron and Zinc in Chronic MS Lesions." Acta Neuropathologica 134, no. 1 (July 2017): 929 45-64. https://doi.org/10.1007/s00401-017-1696-8. 930 931 [85] De Stefano, N., A. Giorgio, M. Battaglini, M. Rovaris, M. P. Sormani, F. Barkhof, T. 932 Korteweg, et al. "Assessing Brain Atrophy Rates in a Large Population of Untreated Multiple

- 933 Sclerosis Subtypes." *Neurology* 74, no. 23 (June 8, 2010): 1868–76.
- 934 https://doi.org/10.1212/WNL.0b013e3181e24136.

- 936 [86] Eshaghi, Arman, Ferran Prados, Wallace J. Brownlee, Daniel R. Altmann, Carmen Tur, M.
- 937 Jorge Cardoso, Floriana De Angelis, et al. "Deep Gray Matter Volume Loss Drives Disability
- 938 Worsening in Multiple Sclerosis: Deep Gray Matter Volume Loss." Annals of Neurology 83, no.
- 939 2 (February 2018): 210–22. https://doi.org/10.1002/ana.25145.

940

- 941 [87] Bermel, Robert A, and Rohit Bakshi. "The Measurement and Clinical Relevance of Brain
- 942 Atrophy in Multiple Sclerosis." The Lancet Neurology 5, no. 2 (February 2006): 158–70.
- 943 https://doi.org/10.1016/S1474-4422(06)70349-0.

944

- 945 [88] Zivadinov, R., A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M.
- 946 G. Dwyer, E. M. Frohman, and O. Khan. "Mechanisms of Action of Disease-Modifying Agents
- and Brain Volume Changes in Multiple Sclerosis." *Neurology* 71, no. 2 (July 8, 2008): 136–44.
- 948 https://doi.org/10.1212/01.wnl.0000316810.01120.05.

949

- 950 [89] De Stefano, Nicola, Maria Laura Stromillo, Antonio Giorgio, Maria Letizia Bartolozzi,
- 951 Marco Battaglini, Mariella Baldini, Emilio Portaccio, Maria Pia Amato, and Maria Pia Sormani.
- 952 "Establishing Pathological Cut-Offs of Brain Atrophy Rates in Multiple Sclerosis." Journal of
- 953 Neurology, Neurosurgery & Psychiatry, April 22, 2015, jnnp-2014-309903.
- 954 https://doi.org/10.1136/jnnp-2014-309903.

- 956 [90] Christian Enzinger, Frederik Barkhof, Olga Ciccarelli, Massimo Filippi, Ludwig Kappos,
- 957 Maria A. Rocca, et al. "Nonconventional MRI and Microstructural Cerebral Changes in Multiple
- 958 Sclerosis." Nature Reviews Neurology 11, no. 12 (December 2015): 676–86.
- 959 https://doi.org/10.1038/nrneurol.2015.194.

- 961 [91] Bodini, Benedetta, Mattia Veronese, Daniel García-Lorenzo, Marco Battaglini, Emilie
- 962 Poirion, Audrey Chardain, Léorah Freeman, et al. "Dynamic Imaging of Individual
- 963 Remyelination Profiles in Multiple Sclerosis." Annals of Neurology 79, no. 5 (May 2016): 726–
- 964 38. https://doi.org/10.1002/ana.24620.

965

- 966 [92] Patrikios, P., C. Stadelmann, A. Kutzelnigg, H. Rauschka, M. Schmidbauer, H. Laursen, P.
- 967 S. Sorensen, W. Bruck, C. Lucchinetti, and H. Lassmann. "Remyelination Is Extensive in a Subset
- 968 of Multiple Sclerosis Patients." *Brain* 129, no. 12 (June 9, 2006): 3165–72.
- 969 https://doi.org/10.1093/brain/awl217.

970

- 971 [93] Gracien, RM., Nürnberger, L., Hok, P. et al. Evaluation of brain ageing: a quantitative
- 972 longitudinal MRI study over 7 years. *Eur Radiol* **27,** 1568–1576 (2017).
- 973 <u>https://doi.org/10.1007/s00330-016-4485-1</u>

Tables

976 977

	All Patients (n = 17)		
Age, y, median (range)	36 (25-65)		
Sex, F/M	7/10		
MS phenotype (RRMS/MS)	11/6		
Baseline disease duration, y, median (range)	3.4 (0.3-28)		
Baseline EDSS, median (range)	2.5 (1-6.5)		
Baseline number of relapses, median (range)	RRMS : 2 (1-5)	PMS: N/A	
Disease-modifying treatment	RRMS: First line, n: 5 Second line, n: 6	PMS: Ocrelizumab, n: 2 None, n: 4	

Table 1: Demographic data of the study sample

	EDSS TO	EDSS T1/2	New lesion T1/2	Relapse T1/2	NEDA T1/2	EDSS T1	New lesion T1	Relapse T1	NEDA T1	Time period T0-T1	Score
sub-001	2	2	None	None	YES	2	None	None	YES	30	1
sub-002	1.5	1.5	None	None	YES	1.5	None	None	YES	27	1
sub-003	2	2	None	None	YES	2	None	None	YES	27	1
sub-004	3	3	None	None	YES	3.5	None	None	YES	25	1
sub-005	1	1	None	None	YES	1	None	None	YES	24	1
sub-006	1.5	1.5	None	None	YES	1.5	None	None	YES	24	1
sub-007	2	2	None	None	YES	2	None	None	YES	22	1
sub-008	3.5	4.5	None	N/A	NO	5	None	N/A	NO	51	0
sub-009	2	2.5	None	None	YES	2.5	None	None	YES	57	1
sub-010	6	6	Yes	N/A	NO	6.5	None	None	NO	14	0
sub-011	6	6	None	N/A	YES	6.5	None	N/A	NO	14	1
sub-012	1	1.5	None	None	YES	1.5	None	None	YES	55	1
sub-013	5.5	6	None	N/A	NO	6.5	None	N/A	NO	60	0
sub-014	2.5	3.5	Yes	Yes	NO	3	None	None	YES	57	1
sub-015	4	4.5	None	N/A	NO	5	None	N/A	NO	51	0
sub-016	5	4.5	Yes	N/A	NO	4.5	None	N/A	YES	61	1
sub-017 980	2	3	Yes	Yes	NO	3	Yes	Yes	NO	56	0

Table 2: Longitudinal clinical information and derived disease status score. The time period between T0 and T1 is expressed in months.

	NAWM	NACGM	NADGM
MTsat	0.039 (.011)*	0.017 (.007)*	0.004 (.749)
PD	-0.018 (.670)	0.405 (.225)	0.250 (.552)
R1	0.009 (.139)	0.004 (.471)	0.010 (.111)
R2*	0.295 (.002)*	0.121 (.092)	0.066 (.770)
BPF		-0.884 (.1562)	
LF		21.23 (.1082)	

Table 3: Regression coefficients and their associated p-values (in parentheses) for the effects of X_{status} on the individual ARoC for each qMRI parameter (MTsat, PD, R1 and R2*) and for volumetric measurements (BPF and LF).

^{*} Results significant at p < .05, FDR corrected.

989	
990	Legends of figures
991	
992	Figure 1: Chartflow of data creation and processing (see text). MPM maps were created with
993	the hMRI-toolbox, FLAIR images were directly acquired for both sessions (T0 and T1). A
994	preliminary mask was constructed based on T0 FLAIR. All images (MPM and FLAIR, T0 and
995	T1) were co-registered to the MPM T0 space. Segmentation using USwL allowed to isolate
996	the different tissue classes.
997	
998	Figure 2: Schematic illustration of the NAWM and 3 lesions-related areas: focal FLAIR lesion
999	(dark gray area), initial peripheral lesion detected at TO (medium gray area), later peripheral
1000	lesion detected at T1 (dashed, left, and light gray, right, area).
1001	
1002	Figure 3: Line plots illustrating individual ARoC's for MTsat (left) and R2* (right) in NAWM.
1002	Figure 5: Line plots illustrating individual AROC's for ivitsat (left) and R2* (right) in NAVVIVI.
1003	Each line corresponds to one subject. Dotted lines represent increasing rates.
1004	
1005	Figure 4: Violin plots of significant change rates in microstructure with respect to X_{status} .
1006	From left to right: MTsat in NAWM, MTsat in NACGM, R2* in NAWM. $*P < .05$.
1007	
1008	Figure 5: Microstructural parameters in NAWM and the 3 lesion-related areas, for each scanning time
1009	T0 and T1. P-values were obtained with post-hoc tests on the tissue area effect. * $P < .05$.
1010	
1011	

1012	Appendix A: Supplementary data legends
1013 1014	Supplementary data 1: Multi-echo 3D FLASH acquisition parameters for Siemens Magnetom PRISMA MRI
1015	
1016 1017	Supplementary data 2: Extended demographic data. Age, disease duration, EDSS and relapses values were taken at baseline.
1018	
1019	Supplementary data 3: Additional follow-up clinical data for each subject.
1020	
1021 1022	Supplementary data 4 : Line plots illustrating individual ARoC's for PD (left) and R1 (right) in NAWM. Each line corresponds to one subject. Dotted lines represent increasing rates.
1023	
1024 1025 1026	Supplementary data 5: Differences of lesion class Least Squares Means. First two columns correspond to tissue class labels (0 = NAWM, 1 = Later peripheral lesion, 2 = Initial peripheral lesion, 3 = FLAIR lesion).
1027	
1028	
1029	




Figure 1: Chartflow of data creation and processing (see text). MPM maps were created with the hMRI-toolbox, FLAIR images were directly acquired for both sessions (T0 and T1). A preliminary mask was constructed based on T0 FLAIR. All images (MPM and FLAIR, T0 and T1) were co-registered to the MPM T0 space. Segmentation using USwL allowed to isolate the different tissue classes.




Figure 2: Schematic illustration of the NAWM and 3 lesions-related areas: focal FLAIR lesion (dark gray area), initial peripheral lesion detected at T0 (medium gray area), later peripheral lesion detected at T1 (dashed, left, and light gray, right, area)




Figure 3: Line plots illustrating individual ARoC's for MTsat (left) and R2* (right) in NAWM.

Each line corresponds to one subject. Dotted lines represent increasing rates.




Figure 4: Violin plots of significant change rates in microstructure with respect to X_{status} .

From left to right: MTsat in NAWM, MTsat in NACGM, R2* in NAWM. * P < .05.




Figure 5: Microstructural parameters in NAWM and the 3 lesion-related areas, for each scanning time T0 and T1. P-values were obtained with *post-hoc* tests on the tissue area effect. * P < .05.